Essential Premium

Life Science IPOs Catch a Second Wind

Kailera Therapeutics’ blockbuster debut and strong aftermarket performance are emboldening biotech issuers — many backed by hedge funds — to test markets again.

Irenic Takes Activist Playbook to a New Industrials SPAC

The firm plans a $220 million blank-check vehicle targeting aerospace, defense, and electrification-linked industrial businesses with established operations.

Sponsored

Optimizing the Efficient Frontier: Opportunistic Credit Amid a Capital Structure Reset

Greenlight’s Recovery Trade Pays Off

A long‑overlooked position in Acadia Healthcare surged in the first quarter, vaulting the stock into Greenlight Capital’s top five holdings.

Related Content

Activist Irenic Capital Quickly Gains Ground

Stephen Taub

Elliott’s Coolheaded Copilot

Julie Segal

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram